Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of NBE Therapeutics.

    Client Virtual Booth

    NBE THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NBE Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Technology Park Basel Hochbergstrasse 60C CH-4057 Basel
    Telephone
    Telephone
    +41 61 633 22 30
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nbe-therapeutics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion

    Details:

    NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors.


    Lead Product(s): NBE-002

    Therapeutic Area: Oncology Product Name: NBE-002

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

    Deal Size: $1,435.6 million Upfront Cash: Undisclosed

    Deal Type: Acquisition December 10, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NBE-Therapeutics Closes USD 22M Series C Financing Round

    Details:

    The funds will enable NBE to advance development of the lead asset NBE-002 through early clinical trials and to further strengthen the development team, management and board of the company.


    Lead Product(s): NBE-002

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

    Deal Size: $22.0 million Upfront Cash: Undisclosed

    Deal Type: Series C Financing January 10, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search